Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW to Urge Insurers to Promote Generic Use among Beneficiaries of High-Cost Healthcare Benefit System
March 18, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
- Govt Denies Intentional Falsification of Data in J-ADNI Study
March 16, 2015
- Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
- 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
March 13, 2015
- PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
- PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
March 12, 2015
- Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
March 11, 2015
- Mandatory CDISC-Based Submissions to Begin in October 2016
March 11, 2015
- Panel OKs 44 More Diseases as Designated Intractable Diseases
March 10, 2015
- MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
- MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
March 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
March 9, 2015
- New Dosage Added to Taxol for Gastric Cancer Treatment
March 9, 2015
- Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
March 6, 2015
- Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
March 6, 2015
- Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
March 6, 2015
- Ishin Submits Bill to Optimize Clinical Research
March 5, 2015
- NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
March 5, 2015
- Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
March 3, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…